Cilta-cel’s ASH 2020 Clinical Updates; Global Regulatory Filings Remain on Track; Allogeneic BCMA CAR-T Enters into Ph1 Trial; Legend’s Q3 2020 Earnings Call Summary

On Monday, November 16, Legend Biotech released their Q3 2020 earnings and financial results (press release), highlighting upcoming ASH 2020 presentations for their BCMA CAR-T cilta-cel (Ph1b/2 CARTITUDE-1 and Ph2 LEGEND-2 trials). Furthermore, management confirmed that cilta-cel’s submission to the FDA and EMA are anticipated by YE 2020 and early 2021, respectively. Finally, Legend commented that in 2021 they anticipate to file cilta-cel with the Chinese NMPA. Below, Celltelligence provides insights on cilta-cel’s global regulatory updates and the potential impact to BMS’s BCMA CAR-T ide-cel.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.